Meghna Das Thakur
Gilead Sciences (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, Melanoma and MAPK Pathways, Colorectal Cancer Treatments and Studies, Computational Drug Discovery Methods
Most-Cited Works
- → Peripheral T cell expansion predicts tumour infiltration and clinical response(2020)776 cited
- → Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance(2013)735 cited
- → Ajuba LIM Proteins Are Negative Regulators of the Hippo Signaling Pathway(2010)260 cited
- → Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial(2018)218 cited
- → Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors(2019)188 cited
- → Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial(2022)142 cited
- → Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy–Mediated Metastatic Melanoma Phenotype(2014)102 cited
- → Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples(2022)95 cited
- → Profiling the heterogeneity of colorectal cancer consensus molecular subtypes using spatial transcriptomics(2024)93 cited
- → 2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC(2021)66 cited